Radiodermatitis is also known as radiation dermatitis/radiation-induced skin reaction (RISR) or radiation injury. It occurs following exposure to high doses of ionizing radiation. This can occur either when patients are irradiated for malignancies; during diagnostic or therapeutic procedures like coronagraphy or fluoroscopy and following nuclear disasters and occupational radiation exposure [1]. Radiodermatitis is the most common complication of roentgen therapy in cancer patients [1] [2].

It typically develops several years following exposure but acute effects can also be seen subsequent to excessive radiation. The clinical presentation depends on the dose, duration, and extent of the area receiving the X-rays. Within 48 hours to 7 days after exposure, the affected skin becomes severely inflamed and patients present with redness, pain, burning sensation, and itching [3] at the site. These symptoms will usually aggravate, subside and then recur with erythema, swelling, and vesicles lasting for up to 30 days accompanied by pustules, and ulceration which can become infected [4] followed by desquamation and necrotic skin changes. Although healing is slow, the recovery is complete in most cases. In some patients, however, lesions may fail to heal especially, if the radiation dose is large.

Delayed effects of radiation, also known as chronic radiodermatitis, may appear up to several years after the end of treatment or exposure and include hypo or hyperpigmentation of the skin, atrophic changes, photosensitivity, telangiectasia and delay in healing of accidental or surgical wounds.

The diagnosis of radiodermatitis depends on the history, and physical examination. The affected individual will usually be able to provide detailed information about acute or long-term radiation exposure at work or for the treatment of a malignancy. A dermatological examination may reveal skin erythema, blisters, ulceration with sloughing in acute cases while hypo or hyperpigmentation with skin atrophy, patchy alopecia, telangiectasia, and fibrosis may be noticed in chronic radiodermatitis.

Biopsy of the affected skin for histopathological examination can help confirm the diagnosis but is rarely performed. As the incidence of secondary bacterial infection is high, a swab from the ulcerated skin for microbiological testing is useful for early detection and management [5] of the condition.

Several subjective grading tools are used to document radiodermatitis [6] [7] [8] [9] [10] [11]. These tools are based on observations performed before starting treatment and then every week during and after completion of radiation therapy.

Treatment for radiodermatitis focuses on relieving symptoms and promoting skin healing. Mild cases may be managed with topical moisturizers and corticosteroids to reduce inflammation. For more severe cases, wound care, including dressings and topical antibiotics, may be necessary to prevent infection. In some instances, treatment may involve reducing the radiation dose or altering the treatment schedule.

The prognosis for radiodermatitis varies depending on the severity of the condition and the patient's overall health. Mild cases often resolve with appropriate skin care and time. However, severe cases may lead to chronic skin changes or complications such as infection. Early intervention and proper management can significantly improve outcomes.

Radiodermatitis is caused by exposure to ionizing radiation, which damages the skin cells. This exposure is most commonly associated with radiation therapy used in cancer treatment. The risk of developing radiodermatitis increases with higher radiation doses, prolonged exposure, and certain individual factors such as skin type and genetic predisposition.

Radiodermatitis is a common side effect of radiation therapy, affecting a significant number of cancer patients. The incidence varies depending on the type of cancer, the radiation dose, and the treatment area. It is more prevalent in patients receiving high-dose radiation or those with pre-existing skin conditions.

The pathophysiology of radiodermatitis involves damage to the skin's cellular structure caused by ionizing radiation. This damage leads to inflammation, impaired skin barrier function, and reduced ability to repair and regenerate. The severity of the condition is influenced by factors such as radiation dose, fractionation (how the dose is divided over time), and individual skin sensitivity.

Preventing radiodermatitis involves minimizing skin exposure to radiation and implementing protective measures. Strategies include using advanced radiation techniques to target tumors more precisely, applying topical agents to protect the skin, and educating patients on proper skin care during treatment. Regular monitoring and early intervention can also help prevent severe cases.

Radiodermatitis is a skin condition resulting from exposure to ionizing radiation, commonly seen in cancer patients undergoing radiation therapy. It presents with a range of skin changes, from mild redness to severe ulceration. Diagnosis is based on clinical evaluation and treatment history. Management focuses on symptom relief and skin healing, with a prognosis that varies depending on severity. Understanding the etiology, epidemiology, and pathophysiology of radiodermatitis is crucial for effective prevention and treatment.

If you are undergoing radiation therapy, it's important to be aware of the potential for radiodermatitis. This condition can cause skin changes such as redness, itching, and peeling in the treated area. To manage these symptoms, follow your healthcare provider's advice on skin care, which may include using moisturizers and avoiding irritants. If you notice any severe skin changes, inform your medical team promptly for appropriate management. Regular monitoring and early intervention can help prevent complications and improve your comfort during treatment.

1. Singh M, Alavi A, Wong R, Sadanori A. Radiodermatitis: A Review of Our Current Understanding. Am J Clini Dermatol. 2016 Jun;17:3:277-292
2. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47:13–47.
3. Noble-Adams R. Radiation-induced reactions 1: an examination of the phenomenon. Br J Nurs. 1999;8(17):1134–1140.
4. Hill A, Hanson M, Bogle MA, Duvic M. Severe radiation dermatitis is related to Staphylococcus aureus. Am J Clin Oncol. 2004;27:361–3.
5. Altoparlak U, Koca O, Koca T. Incidence and Risk Factors of the Secondary Skin Infections in Patients with Radiodermatitis. Eurasian J Med. 2011 Dec;43(3):177–181.
6. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346.
7. National Cancer Institute Cancer Therapy Evaluation Program. Common terminology criteria for adverse events [v.4.03]. Bethesda, MD: National Cancer Institute. 2010. Available: https://evs.nci.nih.gov/ftp1/CTCAE
8. Berthelet E, Truong PT, Musso K, et al. Preliminary reliability and validity testing of a new Skin Toxicity Assessment Tool (STAT) in breast cancer patients undergoing radiotherapy. Am J Clin Oncol. 2004;27:626–631.
9. Catlin-Huth C, Haas ML, Pollock V (Eds). Radiation therapy patient care record: A tool for documenting nursing care. Pittsburgh, PA: Oncology Nursing Society. 2002
10. Noble-Adams R. Radiation-induced skin reactions 2: Development of a measurement tool. Br J Nurs. 1999a;8:1208–1211.
11. Noble-Adams R. Radiation-induced skin reactions 3: Evaluating the RISRAS. Br J Nurs. 1999b;8:1305–1312.